Corcept Therapeutics surges as investors focus on a sizable insider buy and relacorilant’s next regulatory catalyst

Corcept Therapeutics (CORT) is up 30.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to renewed bullish positioning after a large open-market insider purchase disclosed in mid-March, which can be read as a confidence signal following months of volatility. The rally may also reflect traders refocusing on relacorilant’s ovarian-cancer regulatory timeline (a July 2026 FDA decision date), with short-covering potentially amplifying the upside after prior declines.

Details:

A Corcept director reported buying 100,000 shares on March 17, 2026 at an average price around $33.14 (about $3.31 million total), standing out as a rare recent insider purchase for the company.

Corcept has an FDA review underway for relacorilant in platinum-resistant ovarian cancer, with a PDUFA target action date of July 11, 2026 disclosed by the company in prior filings and releases.

Corcept has highlighted Phase 3 ROSELLA results in ovarian cancer as part of its relacorilant program, which has been a key driver of investor interest despite earlier regulatory setbacks in a different relacorilant indication.

After the late-2025 FDA Complete Response Letter in hypercortisolism and subsequent legal/patent headlines, positioning in CORT has been sensitive to any positive signal, making a momentum-driven rebound more likely.

Sources:

MarketBeat, Corcept Therapeutics (Investor Relations), SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CORT Insider Trading Activity

$CORT insiders have traded $CORT stock on the open market 32 times in the past 6 months. Of those trades, 2 have been purchases and 30 have been sales.

Here’s a breakdown of recent trading of $CORT stock by insiders over the last 6 months:

JOSEPH K BELANOFF (Chief Executive Officer) has made 0 purchases and 8 sales selling 120,000 shares for an estimated $9,577,167.
WILLIAM GUYER (Chief Development Officer) has made 0 purchases and 11 sales selling 124,500 shares for an estimated $7,512,565.
SEAN MADUCK (See Remarks) has made 0 purchases and 5 sales selling 60,000 shares for an estimated $4,771,537.
G LEONARD JR BAKER has made 2 purchases buying 100,000 shares for an estimated $3,313,808 and 0 sales.
JOSEPH DOUGLAS LYON (See Remarks) has made 0 purchases and 5 sales selling 15,000 shares for an estimated $1,189,641.
DANIEL N JR SWISHER sold 2,200 shares for an estimated $192,588

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$CORT Hedge Fund Activity

We have seen 166 institutional investors add shares of $CORT stock to their portfolio, and 300 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CITADEL ADVISORS LLC added 751,465 shares (+673.4%) to their portfolio in Q4 2025, for an estimated $26,150,981
GEODE CAPITAL MANAGEMENT, LLC added 734,646 shares (+38.0%) to their portfolio in Q4 2025, for an estimated $25,565,680
CLEARBRIDGE INVESTMENTS, LLC removed 654,474 shares (-56.3%) from their portfolio in Q4 2025, for an estimated $22,775,695
AQR CAPITAL MANAGEMENT LLC removed 619,348 shares (-41.1%) from their portfolio in Q4 2025, for an estimated $21,553,310
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 605,814 shares (-74.7%) from their portfolio in Q4 2025, for an estimated $21,082,327
DRIEHAUS CAPITAL MANAGEMENT LLC removed 526,602 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $18,325,749
SYNERGY ASSET MANAGEMENT, LLC removed 506,856 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $17,638,588

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$CORT Analyst Ratings

Wall Street analysts have issued reports on $CORT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 01/02/2026

To track analyst ratings and price targets for $CORT, check out Quiver Quantitative's $CORT forecast page.

$CORT Price Targets

Multiple analysts have issued price targets for $CORT recently. We have seen 3 analysts offer price targets for $CORT in the last 6 months, with a median target of $95.0.

Here are some recent targets:

Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $60.0 on 02/25/2026
Edward Nash from Canaccord Genuity set a target price of $100.0 on 01/23/2026
Ashwani Verma from UBS set a target price of $95.0 on 12/16/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.